Melanie Leveridge

GlaxoSmithKline (GSK)

Versatile Liquid Handling System Reduces Overall Cycle Times at GSK

In this video, Melanie Leveridge, Head of Screening, Profiling and Mechanistic Biology at GlaxoSmithKline (GSK), Stevenage, UK, discusses her team’s goal of reducing overall cycle times in early drug discovery. Leveridge explains how her team closely collaborated with TTP Labtech in the design and development of the dragonfly® discovery liquid handling system that has accelerated assay development time.



LIKE 2
Melanie Leveridge
ELRIG SLAS2020 Drug discovery

Melanie Leveridge

Biography

Melanie is the head of the... More
Follow Melanie

Melanie Leveridge

GlaxoSmithKline (GSK)

Melanie is the head of the Screening Profiling and Mechanistic Biology department, at the GSK Medicines Research Centre in Stevenage, UK within the global NCE (New Chemical Entity) molecular discovery organization. She leads a department of 40 scientists to partner with therapy area units to select the best targets for small molecule approaches and build assays and mechanistic approaches to understand target:molecule interactions using a range of biochemical, biophysical, cellular and phenotypic assay approaches.